Move Over CannTrust (TSX:TRST): This Pot Stock Has Its Own Regulatory Woes!

After admitting to unlicensed growing in a Niagara facility, Hexo Corp (TSX:HEXO)(NYSE:HEXO) is facing regulatory issues

| More on:
Financial technology concept.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The CannTrust Holdings Inc (TSX:TRST)(NYSE:CTST) regulatory scandal was one of the biggest cannabis stories of 2019.

When a medium-sized cannabis producer was found growing cannabis in unlicensed rooms, it sent shockwaves through the industry. Not only was CannTrust forced to destroy copious amounts of its product, but it also lost its licenses and had the Ontario Cannabis Store return $2.9 million worth of cannabis.

Naturally, the scandal sent CannTrust’s stock tumbling. Other cannabis stocks started falling at the same time, possibly on the sentiment that other producers could be caught up in similar drama.

If it could happen to CannTrust, the theory went, it could happen to anybody else–particularly given the rush to get cannabis ready for legalization and the corner-cutting that resulted.

Now it appears that sentiment was correct, as another cannabis producer is facing heat over unlicensed growing. Although this company is so far getting more merciful treatment from Health Canada than CannTrust did, its problems are the first confirmation we’re getting that CannTrust’s problems aren’t confined to that company.

Depending on how this plays out, we could be seeing the beginning of an industry-wide scandal that keeps stock prices low for the foreseeable future.

Hexo Corp

Hexo Corp (TSX:HEXO)(NYSE:HEXO) is a small-cap cannabis producer best known for its ventures in cannabis-infused beverages. Having started a joint venture with Molson Coors Brewing, it’s better positioned for mass distribution of cannabis beverages than any of its competitors.

The company is also a huge growth success, having increased revenue by 993% year over year in its most recent quarter. Although it lost money in the same quarter, that kind of growth is something worth noting in itself.

Why it’s destroying its cannabis

In May of 2019, Hexo acquired a Niagara cannabis facility from Newstrike Brands.

A few months afterward, it discovered unlicensed growing at the facility and immediately notified Health Canada. Prior to this, Health Canada itself inspected the facility, but found no unlicensed growing.

After discovering the unlicensed activity at its own facilities and notifying Health Canada, CannTrust destroyed all the product originated in unlicensed areas. This echoes what happened earlier with CannTrust, although Hexo has been given far more lenient treatment from Health Canada, which said it was “satisfied” with the company’s corrective actions.

Reasons for optimism

Although the similarities between Hexo and CannTrust are hard to deny, there are many differences between the two situations that provide reason for optimism.

First, Hexo voluntarily found and reported its own unlicensed growing, whereas CannTrust had its unlicensed rooms reported by a whistle blower.

Second, Hexo inherited its unlicensed areas after an acquisition, whereas CannTrust’s were homegrown.

Third, Hexo has received express confirmation from Health Canada that the agency was satisfied with its corrective actions, something that CannTrust didn’t receive.

These factors provide optimism that Hexo won’t lose its license. Nonetheless, the fact that a second cannabis producer discovered unlicensed growing at one of its facilities could be an early signal of trouble for the industry–even if Hexo itself appears safe for now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned. The Motley Fool recommends CannTrust Holdings, CannTrust Holdings Inc, HEXO., and HEXO.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »